Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

TP53 G ene a llelic State in Myelodysplastic Syndromes (MDS) with Isolated 5q Deletion

Blood (2023) 142 (Supplement 1): 1001.

https://doi.org/10.1182/blood-2023-179171

Published: 2023

Journal Articles

Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndromes (MDS)

Cristina Astrid Tentori, Caterina Gregorio, Marie Robin, Nico Gagelmann, Carmelo Gurnari, Somedeb Ball, Juan Carlos Caballero Berrocal, Luca Lanino, Saverio D'Amico, Marta Spreafico, Giulia Maggioni, Erica Travaglino, Elisabetta Sauta, Manja Meggendorfer, Lin-Pierre Zhao, Massimo Bernardi, Carmen Di Grazia, Luca Vago, Giulia Rivoli, Lorenza Maria Borin, Patrizia Chiusolo, Luisa Giaccone, Maria Teresa Voso, Jan Philipp Bewersdorf, Olivier Nibourel, Marina Díaz-Beyá, Andres Jerez, Francisca Maria Hernandez, Kyra Velázquez Kennedy, Blanca Xicoy, Marta Ubezio, Alessia Campagna, Antonio Russo, Gabriele Todisco, Daniele Mannina, Stefania Bramanti, Matteo Zampini, Elena Riva, Marilena Bicchieri, Gianluca Asti, Filippo Viviani, Alessandro Buizza, Benedetta Tinterri, Andrea Bacigalupo, Alessandro Rambaldi, Francesco Passamonti, Fabio Ciceri, Victor Savevski, Armando Santoro, Najla H Al Ali, David A Sallman, Francesc Sole, Guillermo Garcia-Manero, Ulrich Germing, Shahram Kordasti, Valeria Santini, Guillermo Sanz, Wolfgang Kern, Anne Sophie Kubasch, Uwe Platzbecker, Maria Diez-Campelo, Jaroslaw P. Maciejewski, Lionel Ades, Pierre Fenaux, Torsten Haferlach, Amer M. Zeidan, Gastone Castellani, Rami S. Komrokji, Francesca Ieva, Matteo Giovanni Della Porta

Blood (2023) 142 (Supplement 1): 197.

https://doi.org/10.1182/blood-2023-182194

Published: 2023

Journal Articles

Single Cell Multi-Omic Dissection of Response and Resistance to Chimeric Antigen Receptor T Cells Against BCMA in Relapsed Multiple Myeloma

Blood (2023) 142 (Supplement 1): 453.

https://doi.org/10.1182/blood-2023-187371

Published: 2023

Journal Articles

Clinical Text Reports to Stratify Patients Affected with Myeloid Neoplasms Using Natural Language Processing

Blood (2023) 142 (Supplement 1): 122.

https://doi.org/10.1182/blood-2023-188292

Published: 2023

Journal Articles

Synthetic Histopathological Images Generation with Artificial Intelligence to Accelerate Research and Improve Clinical Outcomes in Hematology

Blood (2023) 142 (Supplement 1): 902.

https://doi.org/10.1182/blood-2023-187521

Published: 2023

Journal Articles

Impact of Mutational Burden and IPSS-M on Response to ESAs in Lower Risk Myelodysplastic Neoplasms

Blood (2023) 142 (Supplement 1): 4595.

https://doi.org/10.1182/blood-2023-189053

Published: 2023

Journal Articles

Combining Gene Mutation with Transcriptomic Data Improves Outcome Prediction in Myelodysplastic Syndromes

Blood (2023) 142 (Supplement 1): 1863.

https://doi.org/10.1182/blood-2023-186222

Published: 2023

Journal Articles

Single-Cell Multi-Omics of Peripheral Blood Reveals Tiding and Evolution of Responsive and Resistant Clones upon Daratumumab-Based Treatments in Multiple Myeloma and Plasma Cell Leukemia

Blood (2022) 140 (Supplement 1): 4207–4208.

https://doi.org/10.1182/blood-2022-166241

Published: 2022

Journal Articles

Activation of Distinct Inflammatory Pathways in LR-MDS Is Determined By Genetics

Marie Schneider, Clara Rolfs, Matthias Trumpp, Susann Winter, Luise Fischer, Mandy Richter, Victoria Menger, Kolja Nenoff, Nora Grieb, Anne Sophie Kubasch, Klaus H. Metzeler, Katja Sockel, Christian Thiede, Lorenz C Hofbauer, Andreas Roth, Andreas Bruederle, Janghee Woo, Michael Cross, Uwe Platzbecker

Blood (2022) 140 (Supplement 1): 4011–4012.

https://doi.org/10.1182/blood-2022-163246

Published: 2022

Journal Articles

Molecular Characterization of Clinical Response in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome Patients Treated with Single Agent Emavusertib

Klaus H. Metzeler, Eric S. Winer, Uwe Platzbecker, Amit Verma, Daniel J. DeAngelo, Stefano R. Tarantolo, David A. Sallman, James Dugan, Stefanie Gröpper, Katharina S. Goetze, Chia-Cheng Li, Wanying Zhao, Maureen Lane, Reinhard von Roemeling, Samantha Carlisle, Anne Weigert, Matthias Böhme, Anne Sophie Kubasch, Guillermo Garcia-Manero

Blood (2022) 140 (Supplement 1): 9048–9049.

https://doi.org/10.1182/blood-2022-167477

Published: 2022

Journal Articles

Predicting Early Relapse for Patients with Multiple Myeloma through Machine Learning

Anne Sophie Kubasch, Nora Grieb, Alexander Oeser, Thomas Neumuth, Olaposi Yomade, Andreas Hochhaus, Uwe Platzbecker, Maximilian Merz

Blood (2021) 138 (Supplement 1): 2953.

https://doi.org/10.1182/blood-2021-151195

Published: 2021

Journal Articles

Characterization of Somatic Mosaicism and Mutational Profiling of Clonal Hematopoiesis Compared to MDS and sAML Depicts Diversities of Clonal Evolution

Blood (2021) 138 (Supplement 1): 3278.

https://doi.org/10.1182/blood-2021-152187

Published: 2021

Journal Articles

A Molecular-Based Response Prediction Model to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndrome and Severe Thrombocytopenia

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-139291

Published: 2020

Journal Articles

Efficacy and Safety of Bemcentinib in Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Failing Hypomethylating Agents

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-140240

Published: 2020

Journal Articles

Biomarkers of Response to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndrome (MDS) and Thrombocytopenia - Results of the Europe Trial By the Emsco Network

Blood (2019) 134 (Supplement_1): 2998.

https://doi.org/10.1182/blood-2019-129047

Published: 2019

Journal Articles

Azacitidine for Pre-Emptive Treatment of Measurable-Residual Disease in MDS/AML Patients at High Risk of Hematological Relapse: Results of the Second Cohort of the RELAZA2 Trial

Blood (2019) 134 (Supplement_1): 644.

https://doi.org/10.1182/blood-2019-129926

Published: 2019

Journal Articles

The Role of PPM1D Mutations in Lenalidomide Resistance and Progression in Patients with MDS and Deletion of Chromosome 5q

Blood (2018) 132 (Supplement 1): 4360.

https://doi.org/10.1182/blood-2018-99-114026

Published: 2018

Journal Articles

Anti-CD123 Targeted Therapy with Talacotuzumab in Advanced MDS and AML after Failing Hypomethylating Agents - Final Results of the Samba Trial

Anne Sophie Kubasch, MD, Freya Schulze, Katharina S. Götze, MD, Jan Krönke, MD, Katja Sockel, MD, Jan Moritz Middeke, MD, Fatiha Chermat, Silke Gloaguen, MSc, Martin Puttrich, Carmen Weigt, Katja Jersemann, Pierre Fenaux, MD PhD, Richard F. Schlenk, MD, Aristoteles Giagounidis, Lionel Ades, MD PhD, Anna Mies, Uta Oelschlaegel, Uwe Platzbecker

Blood (2018) 132 (Supplement 1): 4045.

https://doi.org/10.1182/blood-2018-99-113112

Published: 2018

NARROW

TP53 G ene a llelic State in Myelodysplastic Syndromes (MDS) with Isolated 5q Deletion

Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndromes (MDS)

Single Cell Multi-Omic Dissection of Response and Resistance to Chimeric Antigen Receptor T Cells Against BCMA in Relapsed Multiple Myeloma

Clinical Text Reports to Stratify Patients Affected with Myeloid Neoplasms Using Natural Language Processing

Synthetic Histopathological Images Generation with Artificial Intelligence to Accelerate Research and Improve Clinical Outcomes in Hematology

Impact of Mutational Burden and IPSS-M on Response to ESAs in Lower Risk Myelodysplastic Neoplasms

Combining Gene Mutation with Transcriptomic Data Improves Outcome Prediction in Myelodysplastic Syndromes

Single-Cell Multi-Omics of Peripheral Blood Reveals Tiding and Evolution of Responsive and Resistant Clones upon Daratumumab-Based Treatments in Multiple Myeloma and Plasma Cell Leukemia

Activation of Distinct Inflammatory Pathways in LR-MDS Is Determined By Genetics

Molecular Characterization of Clinical Response in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome Patients Treated with Single Agent Emavusertib

Predicting Early Relapse for Patients with Multiple Myeloma through Machine Learning

Characterization of Somatic Mosaicism and Mutational Profiling of Clonal Hematopoiesis Compared to MDS and sAML Depicts Diversities of Clonal Evolution

A Molecular-Based Response Prediction Model to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndrome and Severe Thrombocytopenia

Efficacy and Safety of Bemcentinib in Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Failing Hypomethylating Agents

Biomarkers of Response to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndrome (MDS) and Thrombocytopenia - Results of the Europe Trial By the Emsco Network

Azacitidine for Pre-Emptive Treatment of Measurable-Residual Disease in MDS/AML Patients at High Risk of Hematological Relapse: Results of the Second Cohort of the RELAZA2 Trial

The Role of PPM1D Mutations in Lenalidomide Resistance and Progression in Patients with MDS and Deletion of Chromosome 5q

Anti-CD123 Targeted Therapy with Talacotuzumab in Advanced MDS and AML after Failing Hypomethylating Agents - Final Results of the Samba Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only